Managing Partner of 5AM Ventures, Scott M. Rocklage, through his company Expansion Therapeutics, is leading the drive for increased funding and research into genetic disorders. Primary among these disorders is the the culprit for the majority of muscular dystrophy cases around the world: myotonic dystrophy type 1. This disorder is caused by RNA cells that have reached a toxic level. Rocklage, Expansion Therapeutics, and a slew of other major backers (including Sanofi Ventures, Novartis Venture Fund, and Kleiner Perkins), are working to develop a new medication that will help target these RNA malfunctions in the hopes of curing this disorder. According to Rocklage, the lead scientist on this project is Matthew D. Disney, PhD. Dr. Disney has worked for over 12 years on similar projects, and seems to be the best fit for this noble endeavor.
Scott M. Rocklage earned his Bachelor of Science degree from the University of California at Berkeley and his PhD in Chemistry from the Massachusetts Institute of Technology. During his doctoral work at MIT, Rocklage worked underneath Richard R. Schrock, who won the Nobel Prize for Chemistry in 2005. Today, Rocklage is a founding partner of the 5AM Ventures capital firm, which he claims is a life science-based firm. He is responsible for leading the charge for FDA approval for three different US Medications: Omniscan, Teslascan, and Cubicin. Omniscan and Teslascan are used for imaging in MRIs, while Cubicin is used to treat different forms of infections (including staph infections).
Rocklage claims over thirty years’ experience in healthcare management, and is an inventor in his own right with over thirty patents to his name. He has served as the Board Chairman for various companies, including Relypsa, Achaogen, and Novira, and is currently serving as the Board Chairman for Cidara, Kinestral, and Rennovia. Today, he lives in Boston, MA, where he operates out of his local 5AM Ventures office.
On July 18, 2016, Rocklage and his wife, Patty, were honored by MIT for their generous gift to help fund the renovation of several nanochemistry and nanotechnology labs at the university. At age 82, Rocklage has lived an eventful and successful life and, as MIT was his home for his PhD studies, did not hesitate in providing funding for his old stomping grounds.
Connect with Dr. Scott Rocklage on LinkedIn.